Clinical TrialJun 3, 2026, 06:06 AM
MannKind Advances Nintedanib DPI; Phase 1b Data Expected Q3 2026
AI Summary
MannKind Corporation announced significant progress in its nintedanib DPI program for idiopathic pulmonary fibrosis (IPF), completing patient randomization in the Phase 1b INFLO-1 trial and enrolling the first patient in the global Phase 2 INFLO-2 study. The company anticipates reporting data from the INFLO-1 study in Q3 2026, which will provide initial safety, tolerability, and pharmacokinetic assessments. This inhaled therapy aims to deliver nintedanib directly to the lungs, potentially improving tolerability and adherence compared to the oral version.
Key Highlights
- MannKind completed patient randomization in the U.S. Phase 1b INFLO-1 clinical trial.
- The first patient was enrolled in the global Phase 2 INFLO-2 study for nintedanib DPI.
- Phase 1b INFLO-1 study data readout is anticipated in Q3 2026.
- The Phase 2 INFLO-2 study is expected to enroll approximately 210 participants worldwide.
- Nintedanib DPI leverages Technosphere® dry powder inhalation technology for direct lung delivery.
- The therapy aims to achieve therapeutic concentrations while reducing systemic exposure.
Price Impact
More from MNKD